CAR-T vs. Stem Cell Transplant for New Myeloma Patients
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares a new immune cell therapy (CAR-T) with a standard stem cell transplant to see which works better for people newly diagnosed with multiple myeloma. It aims to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple myeloma (a type of blood cancer).
- You are healthy enough to be considered for a stem cell transplant.
- Your liver function tests (ALT and AST) are less than 3 times the normal upper limit.
- You are able to care for yourself (Karnofsky score over 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.